Artemis Neuroscience Inc., VistaGen deal

VistaGen acquired Artemis, which develops therapeutics for epilepsy, neuropathic pain and other CNS disorders. Through the acquisition, VistaGen added to its pipeline Artemis' AV-101, a preclinical compound for epilepsy. VistaGen believes the indirectly acting NMDA receptor antagonist may have a better side-effect and safety profile than marketed products. The company plans to submit an IND for the compound early in 2005. ...